On June 28, 2016, IM Capital finalized the matching capital investment terms in MEACOR, a company looking to create a less invasive heart valve repair device to treat valvular disease. MeaCor was co-founded by Toufic Azar, PhD student in Biomedical Engineering at Mcgill University, and Dr. Renzo Cecere, Chief Medical Officer and Surgical Director of Heart Failure and Thoracic Transplant Program at McGill University Health Centre. Mitral Valve Regurgitation (MVR) is the second most common heart valve disease and it usually requires open-heart surgery. However, a proportion of the elderly patients (65+), cannot undergo open-heart surgery due to risks that outweigh the benefits. MeaCor is thus developing a novel catheter that enables the accurate positioning and attachment of an implant around the mitral valve annulus (ring) through a minimally invasive approach, that aims at reducing the area of the valve and stopping regurgitation. The Company plans to continue product development at university-sponsored research facilities at both McGill University and AUB.